# Coherus Oncology, Inc. (CHRS) · Edgar & Edgarette company card

> Coherus Oncology (CHRS) grew revenue 59.8% in FY2025 to $42 million, operating margin -430% against a -15.8% median for biological products, (no diagnostic substances), equity 23.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1512762 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CHRS) · [JSON](https://www.pops4.com/boards/company/CHRS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $42M |
| Revenue growth, 1 year | 59.8% |
| Revenue growth per year | -40.1% |
| Operating margin | -429.5% (prior year -756.6%) |
| Net margin | 398.4% |
| Operating cash flow | −$139M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $89M |
| Long-term debt | — |
| Total assets | $258M |
| Total equity | $61M |
| Equity ÷ assets | 23.6% |
| Return on equity | 275.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -20.15 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: 2.83 (above the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed auditor change in the last 12 months; slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -429.5% in FY2025; revenue is hard to predict: its 80% range is ±61%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $42.2M (FY2025). Experience: revenue up 59.8% on the year, down 40.1% a year over 4 years; operating margin -429.5%, up from -756.6%. Soundness: equity 23.6% of assets, return on equity 275.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $22.1M and $92.6M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $20.1M to $102.6M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -429.5% against a -15.8% median; growth 59.8% against 21.4%.

Range logged 2026-10-01, receipt b2bacd2612130bea, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 4.01 Auditor change: 1, latest 2026-06-15 ([filing](https://www.sec.gov/Archives/edgar/data/1512762/000110465926074090/0001104659-26-074090-index.htm))

## Recent filings

- 8-K · filed 2026-10-29 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1512762/000110465926119912/0001104659-26-119912-index.htm)
- 8-K · filed 2026-08-28 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1512762/000110465926103316/0001104659-26-103316-index.htm)
- 8-K · filed 2026-08-17 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1512762/000110465926097951/0001104659-26-097951-index.htm)
- 8-K · filed 2026-08-17 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1512762/000110465926097949/0001104659-26-097949-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/1512762/000110465926091262/0001104659-26-091262-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/0001104659-26-091188-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001512762.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1512762

## Cite

POPS4, Edgar & Edgarette: Coherus Oncology, Inc. (CHRS) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/CHRS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.